Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeted therapy for malignant gliomas.

Andrew P Morokoff1, Ulrike Novak

  • 1Department of Surgery, Royal Melbourne Hospital, University of Melbourne, Melbourne, Victoria, Australia. a_morokoff@hotmail.com

Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia
|November 3, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Activating Ras-MAPK pathway variants drive hippocampal clonal competition in human epilepsy.

bioRxiv : the preprint server for biology·2026
Same author

The UMPIRE study: A first-in-human multicenter trial of bilateral subscalp monitoring for epileptic seizure detection.

Epilepsia·2025
Same author

Plasma ctDNA enables early detection of temozolomide resistance mutations in glioma.

Neuro-oncology advances·2024
Same author

Plasma ctDNA liquid biopsy of IDH1, TERTp, and EGFRvIII mutations in glioma.

Neuro-oncology advances·2024
Same author

Amygdala enlargement in temporal lobe epilepsy: Histopathology and surgical outcomes.

Epilepsia·2024
Same author

Signaling pathways underlying TGF-β mediated suppression of IL-12A gene expression in monocytes.

Molecular immunology·2024

Targeted therapies using monoclonal antibodies and tyrosine kinase inhibitors show promise for cancer treatment. Overcoming delivery challenges to brain tumors is key for realizing the potential of these novel agents.

Area of Science:

  • Oncology
  • Pharmacology
  • Biotechnology

Background:

  • Tumor-specific markers enable targeted therapies with fewer side effects than traditional treatments.
  • Monoclonal antibodies and tyrosine kinase inhibitors represent advanced therapeutic strategies.
  • Targeted agents offer a promising paradigm shift in cancer treatment.

Purpose of the Study:

  • To review the development and potential of targeted therapies in oncology.
  • To discuss the application of monoclonal antibodies and tyrosine kinase inhibitors.
  • To highlight challenges and future directions in targeted cancer treatment.

Main Methods:

  • Review of scientific literature on targeted cancer therapies.
  • Analysis of the mechanisms of action for monoclonal antibodies and tyrosine kinase inhibitors.

Related Experiment Videos

  • Discussion of clinical trial outcomes and challenges in drug delivery.

    • Main Results:

    • Targeted therapies, including monoclonal antibodies and tyrosine kinase inhibitors, demonstrate efficacy.
    • Tyrosine kinase inhibitors have shown significant impact in hematological malignancies and are being tested in solid tumors.
    • Early results for some targeted agents are encouraging, supporting their theoretical basis.

    Conclusions:

    • Targeted therapies offer a promising approach to cancer treatment with potentially reduced side effects.
    • Further research is needed to identify new molecular targets and develop novel agents.
    • Clinical trials are essential to confirm the safety and efficacy of these innovative treatments.